Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. If you're looking to invest in the small-cap biotech sector, however, patience is essential. Most of these companies are still in the clinical stage, so they have no commercially available drugs or therapeutics. That also means they typically report negative earnings (not profitable) and generate little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. WARNING: Do Not Buy AI Stocks
While NVIDIA wobbles and the Magnificent 7 cool off, there's a backdoor AI play most investors are missing. It's not software. It's not chips. It's the physical infrastructure. The land, buildings, and power that make AI possible. Former Presidential Advisor Brad Thomas says Trump's Executive Orders are about to ignite a boom in this sector. And a small handful of companies are positioned to dominate. He names his top pick - completely free - in this time-sensitive video. Get the name and ticker of his #1 "Mandatory Payout" stock to buy now, FREE Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies usually attract the analyst coverage that brings institutional investment. Getting in early on one of these medical stocks and seeing it succeed can feel like winning the lottery—returns of 3x, 5x or even 10x are possible. Many other names will never pan out, which is why some investors allocate a lump sum equally across multiple biotech positions. If it's a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's digital health pioneers. With more than 60,000 new colorectal cancer cases diagnosed annually in Germany, the market opportunity is meaningful. The company is also developing a non-invasive blood-based screening test for early pancreatic cancer and reported positive topline results in October. That program, however, remains years away from any potential commercial approval. Risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. The company disclosed “Going Concern” language in its Sept. 26 SEC filing and has since filed a $150 million mixed shelf offering. For now, that offering helps keep MYNZ stock above $1 and avoids a delisting notice. Mainz Biomed is racing to generate enough revenue to move the needle. If it succeeds, even a relatively small investment could deliver a sizable return, but the path is uncertain and capital needs are real. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach, but it carries the kind of financial risk speculative investors must carefully weigh. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, neutralizing the pathogens before they can infect real cells. It's an innovative concept that, if validated in human trials, could represent a fundamentally new method for treating infectious diseases. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. As with many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on new capital to advance its programs. Recent filings indicate limited cash on hand, so investors should expect potential dilution. Still, if even one candidate progresses into clinical development successfully, the valuation upside could be meaningful. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space. As always with speculative small-cap biotech names, consider position sizing and diversification to manage the high probability of failure alongside the small chance of a big payoff.
| 
